Daptomycin; First And Only Member Of Cyclic Lipopeptide Antibiotics
ŞUA SÜMER
- Year : 2012
- Vol : 28
- Issue : 3
- Page :
205-208
Daptomycin, is currently the first and only member of a new age antibiotics class labeled as cyclic lipopeptides. The spectrum of its effectiveness is limited with gram positive aerobe and anaerobe bacteria. It is effective against; staphylococci including methicillin resistant S.aureus (MRSA), vancomycin intermediately sensitive S.aureus (VISA), vancomycin resistant S.aureus (VRSA), enterococci including E.faecalis and E.faecium, and penicillin resistance streptococci including S.pneumoniae. Daptomycin, first used in the world in 2003, was licensed in our country in 2009. The clinical indications for daptomycin use are the same with other countries; namely, complicated skin and soft tissues infections, and S.aureus bacteremia and S.aureus right sided endocarditis.
Cite this Article As :
Download Citation: Endnote/Zotero/Mendeley (RIS) RIS File
Download Citation: BibTeX BibTeX File
Description :
None of the authors, any product mentioned in this article,
does not have a material interest in the device or drug. Research,
not supported by any external organization.
grant full access to the primary data and, if requested by the magazine
they agree to allow the examination of data.
Daptomycin; First And Only Member Of Cyclic Lipopeptide Antibiotics
2012,
Vol.
28
(3)
Received : 08.03.2011,
Accepted : 08.03.2011,
Published Online : 13.08.2018
Selçuk Tıp Dergisi
ISSN:1017-6616;
E-ISSN:2149-8059;